Leigh's disease
Methodology & AI Transparency ⓘ
Leigh's disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Leigh's disease is an ICD-10-CM indexed diagnosis (G31.82) within Alzheimer, Dementia & Memory Health.
- 2 Real-world patient consensus: Mapped to Alzheimer, Dementia & Memory Health under ICD-10-CM G31.82 for Leigh's disease clinical workups.
- 3 Typical cash cost range: Differential triage of Leigh's disease (G31.82) utilizes hearing/vision optimization [Leigh's disease G31.82].
- 4 Top reported side effects / signs: Follow-up benchmark in Leigh's disease: maintaining MoCA Cognitive Screening in Leigh's disease (G31.82: Score) within >= 26 / 30 (G31.82).
Ask our AI Specialists anything about Leigh's disease
What Is Leigh's disease?
Leigh's disease is an ICD-10-CM indexed diagnosis (G31.82) within Alzheimer, Dementia & Memory Health. Clinical evaluation centers on hearing/vision optimization [Leigh's disease G31.82] alongside serial MoCA Cognitive Screening in Leigh's disease (G31.82: Score) tracking (>= 26 / 30 (G31.82)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Leigh's disease (G31.82) features hippocampal [Leigh's disease G31.82]. therapeutic stabilization in memory & cognition is verified against Homocysteine & Vitamin in Leigh's disease (G31.82: B12).
Common Symptoms & Clinical Signs
- • Presentation of Leigh's disease (G31.82): subtle personality shifts, in Leigh's disease (G31.82: apathy, or evening)
- • Secondary Leigh's disease clinical sign: slowed processing speed in Leigh's disease (G31.82: compared with prior)
- • Symptom flares in Leigh's disease correlating with MoCA Cognitive Screening in Leigh's disease (G31.82: Score) deviation outside >= 26 / 30 (G31.82)
- • Functional memory & cognition impact requiring hearing/vision optimization [Leigh's disease G31.82] evaluation (G31.82)
Leigh's disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G31.82 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Leigh's disease (G31.82: Score) | >= 26 / 30 (G31.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Leigh's disease (G31.82: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Leigh's disease (G31.82: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G31.82) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Leigh's disease
Treatment selection for Leigh's disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Leigh's disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, gold-standard: What a 1,795-Participant Study Found Lecanemab was associated with a relative preservation of HRQoL and less increase in caregiver burden, with consistent benefits seen across different quality of life scales and within scale subdomains. The journal of prevention of Alzheimer's disease • 2023-01-15 • Phase III Randomized Trial | N = 1,795 | 96/100 | PMID 37874099 ↗ |
| New Insights on Cognitive effects of estradiol after menopause: A randomized trial of the timing: What a 567-Participant Study Found Estradiol initiated within 6 years of menopause does not affect verbal memory, executive functions, or global cognition differently than therapy begun 10+ years after menopause. Neurology • 2016-08-16 • Randomized Controlled Trial | N = 567 | 93/100 | PMID 27421538 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term safety of gantenerumab in participants with Alzheimer's disease: A SC gantenerumab at doses of up to 1200 mg Q4W was well tolerated with no unexpected safety findings in participants with prodromal Alzheimer's disease. Journal of Alzheimer's disease : JAD • 2025-01-15 • Phase III Randomized Trial | N = 154 | 88/100 | PMID 39686620 ↗ |
| Can This Approach Help? Inside the Latest Research on Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion Especially on day 120, PD-1 was upregulated on CD4 + T EMRA and T CM , and on CD8 + T EM and T CM cells; accordingly, proliferation and IFN-γ secretion capacities tended to decline after 4 months. Scientific reports • 2023-03-21 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36944716 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase III gold-standard blind, compared against a dummy pill (placebo), These findings suggest that SPP-004 is safe and may provide therapeutic effect for LS patients who achieved an initial clinical response. PloS one • 2026-01-15 • Phase III Randomized Trial | N = 54 | 88/100 | PMID 42467686 ↗ |
Leigh's disease Patient Community & “People Like Me” Threads
Filter Leigh's disease community threads and patient logs by age, biological sex, dosage, and treatment duration.